NASDAQ$HOWL

Werewolf Therapeutics Inc · Q4 2026 earnings

Q4 2026 earnings · · Before market open · Investor relations

Briefing

Werewolf Therapeutics Inc: net income $13.5K, EPS $-0.28 in Q4 fiscal 2025

Werewolf Therapeutics Inc reported Q4 fiscal 2025 results. Per SEC filing 0001785530-26-000012 (10-Q): Net income was $13.5K, down 25.2% from $18.1K; diluted EPS was $-0.28.

  • Net income: $13.5K
  • Diluted EPS: $-0.28
  • Source: 0001785530-26-000012

Headline financials

EPS (adj)

-$0.28

No prior period
Net Income

$13.5K

No prior period

Revenue & EPS history

Werewolf Therapeutics · Revenue · Quarterly

$1.3M

Q3 2025
Beat estimate in 3 of 12 quarters(25%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2026

Historical avgQ4 2026

+0.1%

Avg return

Earnings day

-0.8%

Avg return

5 days after

+4.1%

Avg return

30 days after

52%

12 / 23 earnings

Positive

+16.5%

Q2 2022

Best reaction

-7.4%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-3.5%-2.3%
Q3 2025-5.0%-7.4%-22.0%
Q2 2025-1.5%-5.9%+5.9%
Q1 2025+0.9%-2.7%+9.9%
Q4 2024-0.9%-3.4%-21.5%
Q3 2024-5.7%-11.9%-26.2%
Q1 2024-1.6%-9.9%-15.0%
Q4 2023-7.4%-6.1%-15.8%
Q3 2023-0.9%+3.6%+28.8%
Q2 2023+3.2%-0.8%-0.4%
Q1 2023-3.3%-9.9%+11.2%
Q4 2022+6.1%+9.2%+3.1%
Q3 2022+2.3%-5.0%-19.4%
Q2 2022+16.5%+21.3%+55.2%
Q1 2022+3.3%-12.1%+1.7%
Q4 2021+0.5%+9.5%+12.6%
Q3 2021+1.8%+1.6%-6.7%
Q3 2020+1.8%+1.6%-6.7%
Q2 2021-3.5%-2.7%+13.9%
Q2 2020-3.5%-2.7%+13.9%
Q1 2021+1.0%+5.8%+22.4%
Q1 2020+1.0%+5.8%+22.4%
Q4 2020+1.0%+5.8%+22.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro